0H7R logo

Abeona Therapeutics LSE:0H7R Stock Report

Last Price

US$7.35

Market Cap

US$201.3m

7D

-2.2%

1Y

163.3%

Updated

27 Mar, 2024

Data

Company Financials +

Abeona Therapeutics Inc.

LSE:0H7R Stock Report

Market Cap: US$201.3m

0H7R Stock Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

0H7R fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Abeona Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abeona Therapeutics
Historical stock prices
Current Share PriceUS$7.35
52 Week HighUS$8.80
52 Week LowUS$2.76
Beta1.48
1 Month Change-2.04%
3 Month Change43.18%
1 Year Change163.26%
3 Year Change-84.46%
5 Year Changen/a
Change since IPO-98.19%

Recent News & Updates

Recent updates

Shareholder Returns

0H7RGB BiotechsGB Market
7D-2.2%1.7%2.2%
1Y163.3%-27.5%3.7%

Return vs Industry: 0H7R exceeded the UK Biotechs industry which returned -27.5% over the past year.

Return vs Market: 0H7R exceeded the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0H7R's price volatile compared to industry and market?
0H7R volatility
0H7R Average Weekly Movement14.2%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0H7R's share price has been volatile over the past 3 months.

Volatility Over Time: 0H7R's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a84Vish Seshadrihttps://www.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.

Abeona Therapeutics Inc. Fundamentals Summary

How do Abeona Therapeutics's earnings and revenue compare to its market cap?
0H7R fundamental statistics
Market capUS$201.33m
Earnings (TTM)-US$54.19m
Revenue (TTM)US$3.50m

57.5x

P/S Ratio

-3.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0H7R income statement (TTM)
RevenueUS$3.50m
Cost of RevenueUS$2.69m
Gross ProfitUS$810.00k
Other ExpensesUS$55.00m
Earnings-US$54.19m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.98
Gross Margin23.14%
Net Profit Margin-1,548.23%
Debt/Equity Ratio0%

How did 0H7R perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.